Cancer Gene Therapy is the essential gene and cellular therapy resource for cancer researchers and clinicians, keeping readers up to date with the latest developments in gene and cellular ...

who is now able to hear thanks to gene therapy. It is now 12 months since the Food and Drug Administration rolled out the historic approval of a CRISPR therapy designed for patients suffering from ...

Christmas has come a few days early for Spark Therapeutics after the FDA approved its ground-breaking gene therapy for a rare eye disease. It looked likely that the FDA would approve the US ...

Factor VIII gene was introduced into hematopoietic stem cells in men with hemophilia. The annualized bleeding rate went from 10 to 0. No worrisome gene integrations were seen. The content of this ...

"In the history of heart failure research, we have not seen efficacy like this," Shaw said. "It's night and day." The gene therapy also appeared to improve heart function on a genetic level ...

Pfizer has abandoned development of a hemophilia A gene therapy it licensed from Sangamo Therapeutics, a move that could imperil Sangamo’s future. It’s a sudden turnabout for Pfizer ...

The next year, it acquired the Research Triangle facility of the gene therapy company bluebird bio. Resilience would use the site to make viral vectors, a key part of gene therapies. The company ...

"Our study shows that we can deliver genes to renal tubules and podocytes [highly specialized cells] in the kidney, the two important target cell types for gene therapy, and while there is a ...

Gene therapy has been available since 2022 for hemophilia B and since 2023 for hemophilia A, yet some major medical institutions have barely treated any patients so far. What’s the holdup?

Pfizer gave Sangamo Therapeutics coal for Christmas, terminating a hemophilia A gene therapy pact to deprive the cash-strapped biotech of up to $220 million in milestones. Pfizer’s decision sent ...